Publication | Closed Access

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

B-cell LymphomaLymphoid NeoplasiaHematological MalignancyTransplantationMedicineSalvage TreatmentImmunologyImmunotherapyOncologyCell TransplantationTransplant-ineligible Patients